Eversept Partners LP Purchases Shares of 147,471 Glaukos Corporation $GKOS

Eversept Partners LP purchased a new stake in shares of Glaukos Corporation (NYSE:GKOS) in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 147,471 shares of the medical instruments supplier’s stock, valued at approximately $16,651,000. Glaukos comprises 0.8% of Eversept Partners LP’s portfolio, making the stock its 29th largest position.

Other institutional investors have also made changes to their positions in the company. AustralianSuper Pty Ltd increased its position in shares of Glaukos by 10.8% during the third quarter. AustralianSuper Pty Ltd now owns 449,846 shares of the medical instruments supplier’s stock valued at $36,685,000 after acquiring an additional 43,750 shares during the last quarter. JPMorgan Chase & Co. increased its position in shares of Glaukos by 4.3% during the third quarter. JPMorgan Chase & Co. now owns 670,083 shares of the medical instruments supplier’s stock valued at $54,645,000 after acquiring an additional 27,646 shares during the last quarter. SG Americas Securities LLC increased its position in shares of Glaukos by 460.8% during the fourth quarter. SG Americas Securities LLC now owns 60,232 shares of the medical instruments supplier’s stock valued at $6,801,000 after acquiring an additional 49,492 shares during the last quarter. Allspring Global Investments Holdings LLC increased its position in shares of Glaukos by 32.8% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 355,279 shares of the medical instruments supplier’s stock valued at $39,336,000 after acquiring an additional 87,781 shares during the last quarter. Finally, TD Asset Management Inc acquired a new stake in shares of Glaukos during the third quarter valued at about $1,157,000. 99.04% of the stock is currently owned by institutional investors and hedge funds.

Glaukos Trading Down 0.2%

Shares of GKOS stock opened at $127.32 on Thursday. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.73 and a current ratio of 5.43. The stock has a market capitalization of $7.48 billion, a P/E ratio of -38.82 and a beta of 0.82. The company has a 50 day moving average price of $124.87 and a 200 day moving average price of $116.80. Glaukos Corporation has a fifty-two week low of $73.16 and a fifty-two week high of $148.11.

Glaukos (NYSE:GKOS) last announced its quarterly earnings data on Wednesday, April 29th. The medical instruments supplier reported ($0.18) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.12. The firm had revenue of $150.57 million during the quarter, compared to analysts’ expectations of $137.00 million. Glaukos had a negative net margin of 34.34% and a negative return on equity of 6.92%. The business’s quarterly revenue was up 41.2% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.22) earnings per share. Equities research analysts predict that Glaukos Corporation will post -0.57 EPS for the current fiscal year.

Insider Activity

In other Glaukos news, Director Leana Wen sold 1,700 shares of the business’s stock in a transaction that occurred on Friday, May 1st. The shares were sold at an average price of $143.35, for a total transaction of $243,695.00. Following the completion of the transaction, the director owned 19,739 shares in the company, valued at $2,829,585.65. The trade was a 7.93% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CFO Alex R. Thurman sold 10,000 shares of the business’s stock in a transaction that occurred on Thursday, April 30th. The stock was sold at an average price of $140.00, for a total transaction of $1,400,000.00. Following the transaction, the chief financial officer owned 43,681 shares of the company’s stock, valued at $6,115,340. This trade represents a 18.63% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 45,305 shares of company stock worth $6,259,395. Insiders own 5.90% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on the stock. BTIG Research reiterated a “buy” rating and set a $162.00 price target on shares of Glaukos in a research report on Wednesday, June 10th. Weiss Ratings restated a “sell (d-)” rating on shares of Glaukos in a report on Tuesday, April 21st. William Blair restated an “outperform” rating on shares of Glaukos in a report on Tuesday, May 26th. Stifel Nicolaus set a $170.00 price objective on shares of Glaukos in a report on Thursday, April 30th. Finally, Wells Fargo & Company lifted their price objective on shares of Glaukos from $135.00 to $138.00 and gave the company an “overweight” rating in a report on Thursday, April 30th. Twelve research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Glaukos presently has a consensus rating of “Moderate Buy” and a consensus target price of $149.17.

Glaukos Profile

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.